RU2017121019A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017121019A3 RU2017121019A3 RU2017121019A RU2017121019A RU2017121019A3 RU 2017121019 A3 RU2017121019 A3 RU 2017121019A3 RU 2017121019 A RU2017121019 A RU 2017121019A RU 2017121019 A RU2017121019 A RU 2017121019A RU 2017121019 A3 RU2017121019 A3 RU 2017121019A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306930 | 2014-12-01 | ||
| EP14306930.0 | 2014-12-01 | ||
| PCT/EP2015/078239 WO2016087457A1 (en) | 2014-12-01 | 2015-12-01 | Stable liquid vaccinia virus formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017121019A RU2017121019A (ru) | 2019-01-09 |
| RU2017121019A3 true RU2017121019A3 (enExample) | 2019-05-23 |
| RU2704485C2 RU2704485C2 (ru) | 2019-10-29 |
Family
ID=52002884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017121019A RU2704485C2 (ru) | 2014-12-01 | 2015-12-01 | Стабильные жидкие препараты вируса осповакцины |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10517943B2 (enExample) |
| EP (1) | EP3226894B1 (enExample) |
| JP (1) | JP6655618B2 (enExample) |
| KR (1) | KR102507483B1 (enExample) |
| CN (1) | CN107206063B (enExample) |
| AU (1) | AU2015357225B2 (enExample) |
| DK (1) | DK3226894T3 (enExample) |
| ES (1) | ES2753364T3 (enExample) |
| IL (1) | IL252512B (enExample) |
| MX (1) | MX378901B (enExample) |
| RU (1) | RU2704485C2 (enExample) |
| WO (1) | WO2016087457A1 (enExample) |
| ZA (1) | ZA201703534B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3512939A1 (en) | 2016-09-16 | 2019-07-24 | Leukocare AG | A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
| WO2018050873A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| EP3624845A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| EP3762020A1 (en) | 2018-03-07 | 2021-01-13 | Transgene | Parapoxvirus vectors |
| US12150988B2 (en) | 2018-09-06 | 2024-11-26 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| CA3124773A1 (en) | 2018-12-28 | 2020-07-02 | Transgene | M2-defective poxvirus |
| CN113646047B (zh) * | 2019-02-15 | 2025-07-08 | 印度血清研究所私人有限公司 | 减毒活流感疫苗组合物和用于制备其的方法 |
| PH12022550240A1 (en) * | 2019-08-29 | 2022-12-19 | Astellas Pharma Inc | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
| CN110669739A (zh) * | 2019-09-30 | 2020-01-10 | 长春生物制品研究所有限责任公司 | 一种新型甲型肝炎病毒抗原制备方法 |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| KR20220153587A (ko) | 2020-03-12 | 2022-11-18 | 버베리안 노딕 에이/에스 | 폭스바이러스 안정성을 개선하는 조성물 |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| CN115704011A (zh) * | 2021-08-11 | 2023-02-17 | 北京永泰生物制品有限公司 | 一种高稳定性的慢病毒制剂及其制备方法和其应用 |
| JP2025523573A (ja) | 2022-07-01 | 2025-07-23 | トランジェーヌ | サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質 |
| EP4585699A1 (en) * | 2022-09-09 | 2025-07-16 | BGI Shenzhen | Use of heteroaromatic ring compounds in nucleic acid tests |
| CN117003897B (zh) * | 2023-08-10 | 2024-10-29 | 深圳泰华赛尔生物科技有限公司 | 靶向Claudin18.2的CAR-T细胞及其用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5255054Y2 (enExample) * | 1973-01-12 | 1977-12-13 | ||
| US3915794A (en) * | 1973-02-09 | 1975-10-28 | Rit Rech Ind Therapeut | Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| DK331087A (da) * | 1986-06-30 | 1987-12-31 | Smith Kline Rit | Stabilisator for levende vaccine |
| JPS6314729U (enExample) * | 1986-07-14 | 1988-01-30 | ||
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| GB9001641D0 (en) | 1990-01-24 | 1990-03-21 | Imp Cancer Res Tech | Compounds |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US6241989B1 (en) * | 1991-07-09 | 2001-06-05 | Cornell Research Foundation, Inc. | Recombinant multivalent viral vaccine |
| HU220080B (hu) * | 1992-06-04 | 2001-10-28 | Merck And Co. Inc. | Eljárás gyengített Varicella zoster vírus vakcina előállítására |
| FR2710536B1 (fr) | 1993-09-29 | 1995-12-22 | Transgene Sa | Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire. |
| FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| US7094412B2 (en) | 2001-12-10 | 2006-08-22 | Bavarian Nordic A/S | Poxvirus containing formulations and process for preparing stable poxvirus containing compositions |
| CN101804202B (zh) | 2003-02-25 | 2014-06-18 | 米迪缪尼有限公司 | 制备流感疫苗组合物的方法 |
| FR2855758B1 (fr) | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
| US7790445B2 (en) | 2003-07-21 | 2010-09-07 | Transgene S.A. | Polypeptide having an improved cytosine deaminase activity |
| ATE467678T1 (de) | 2003-07-22 | 2010-05-15 | Vivalis | Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien |
| WO2005066333A1 (en) * | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
| MX2007005379A (es) | 2004-11-05 | 2007-07-04 | Wellstat Biologics Corp | Formulaciones de virus envueltos estables y filtrables. |
| KR101772375B1 (ko) | 2005-09-07 | 2017-08-29 | 신라젠(주) | Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
| AU2007204024B2 (en) | 2006-01-05 | 2012-01-19 | Transgene S.A. | Avian telomerase reverse transcriptase |
| MX2008013489A (es) | 2006-04-21 | 2008-10-30 | Transgene Sa | Vacuna de virus de papiloma basado en hpv-18 (virus de papiloma humano 18). |
| DK2029756T3 (en) | 2006-06-20 | 2017-02-13 | Transgene Sa | PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS |
| KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| EP2176398B1 (en) | 2007-07-03 | 2016-12-28 | Transgene SA | Immortalized avian cell lines |
| AU2008328257B2 (en) | 2007-11-19 | 2013-08-22 | Transgene Sa | Poxviral oncolytic vectors |
| MX2010005273A (es) | 2007-11-19 | 2010-08-31 | Transgene Sa | Vectores oncoliticos poxvirales. |
| US7998488B2 (en) * | 2008-11-14 | 2011-08-16 | Baxter International Inc. | Vaccine formulations and uses thereof |
| BRPI1007744A2 (pt) * | 2009-05-12 | 2017-06-27 | Transgene Sa | método para a produção e purificação de um ortopoxvírus do tipo selvagem, ortopoxvírus do tipo selvagem, composição farmacêutica, uso de um ortopoxvírus do tipo selvagem e uso de uma linhagem de células aviárias imortalizadas |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| TWI638829B (zh) | 2012-07-10 | 2018-10-21 | 法商傳斯堅公司 | 分枝桿菌抗原疫苗 |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
-
2015
- 2015-12-01 US US15/529,668 patent/US10517943B2/en active Active
- 2015-12-01 EP EP15804407.3A patent/EP3226894B1/en active Active
- 2015-12-01 ES ES15804407T patent/ES2753364T3/es active Active
- 2015-12-01 MX MX2017007178A patent/MX378901B/es unknown
- 2015-12-01 RU RU2017121019A patent/RU2704485C2/ru active
- 2015-12-01 KR KR1020177017299A patent/KR102507483B1/ko active Active
- 2015-12-01 AU AU2015357225A patent/AU2015357225B2/en active Active
- 2015-12-01 WO PCT/EP2015/078239 patent/WO2016087457A1/en not_active Ceased
- 2015-12-01 DK DK15804407.3T patent/DK3226894T3/da active
- 2015-12-01 JP JP2017529010A patent/JP6655618B2/ja active Active
- 2015-12-01 CN CN201580075166.2A patent/CN107206063B/zh active Active
-
2017
- 2017-05-23 ZA ZA201703534A patent/ZA201703534B/en unknown
- 2017-05-25 IL IL252512A patent/IL252512B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| RU2704485C2 (ru) | 2019-10-29 |
| ZA201703534B (en) | 2019-10-30 |
| EP3226894B1 (en) | 2019-08-07 |
| US20170326230A1 (en) | 2017-11-16 |
| JP2017537910A (ja) | 2017-12-21 |
| CN107206063B (zh) | 2021-09-28 |
| AU2015357225B2 (en) | 2020-04-09 |
| ES2753364T3 (es) | 2020-04-08 |
| AU2015357225A1 (en) | 2017-06-15 |
| JP6655618B2 (ja) | 2020-02-26 |
| KR20170091653A (ko) | 2017-08-09 |
| KR102507483B1 (ko) | 2023-03-07 |
| RU2017121019A (ru) | 2019-01-09 |
| EP3226894A1 (en) | 2017-10-11 |
| WO2016087457A1 (en) | 2016-06-09 |
| IL252512A0 (en) | 2017-07-31 |
| CN107206063A (zh) | 2017-09-26 |
| MX2017007178A (es) | 2017-08-28 |
| IL252512B (en) | 2020-05-31 |
| CA2969034A1 (en) | 2016-06-09 |
| DK3226894T3 (da) | 2019-10-21 |
| MX378901B (es) | 2025-03-10 |
| US10517943B2 (en) | 2019-12-31 |